Do you want to link to this External Website and leave


Amgen Europe takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.


Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

Amgen in Europe

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen Europe was established in 1989 and today comprises more than 5000 employees engaged in assisting patients across 31 countries in Europe. The European Hub in Rotkreuz, Switzerland, employs around 150 staff members. Amgen’s Swiss affiliate is located in the same building and was established shortly after the Amgen European Commercial headquarters in 1989. Today, the Swiss branch employs around 80 staff members.

Innovative Medicines

Over the past four decades, Amgen has launched an extensive portfolio of innovative medicines, with 17 currently marketed in Europe and the industry’s largest collection of modalities, that tackle some of the world's most serious diseases. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

Complementing its range of innovative biologic drugs, Amgen's biosimilars offer more affordable therapeutic choices for patients in the form of high-quality, reliably supplied medicines and drive value within the healthcare system by building headroom for innovation.